Transcutaneous immunization with pneumococcal surface protein A in mice.

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• Pneumococcal infections caused by Streptococcus pneumoniae pose a significant global health threat, leading to severe illness and mortality.
• Developing safe and effective vaccines is crucial for preventing pneumococcal infections, particularly targeting upper respiratory tract colonization.

Purpose of the Study:

• To investigate the efficacy of transcutaneous immunization (TCI) in inducing immune responses against pneumococcal surface protein A (PspA) within the upper respiratory tract.
• To evaluate the potential of TCI as a strategy for preventing Streptococcus pneumoniae colonization.

Main Methods:

• C57BL/6 mice were immunized transcutaneously with PspA and cholera toxin (CT) multiple times.
• Nasal washes, saliva, and plasma were collected to measure PspA-specific antibody levels via ELISA.
• Mice were subsequently challenged with Streptococcus pneumoniae to assess bacterial colonization in nasal passages.

Main Results:

• Transcutaneous immunization with PspA plus CT significantly increased PspA-specific IgM, IgG, and IgA antibodies in plasma.
• Enhanced PspA-specific secretory IgA (S-IgA) responses were observed in nasal washes and saliva.
• Significantly lower bacterial colony-forming units (CFUs) were found in the nasal passages of immunized mice.

Conclusions:

• Transcutaneous immunization with PspA and CT effectively induces both mucosal and systemic antigen-specific immune responses.
• This TCI approach represents a promising strategy for mucosal immunization against pneumococcal infections.
• TCI demonstrated effectiveness in blocking Streptococcus pneumoniae colonization of the nasal cavity.